Pandemic influenza: Antiviral preparedness and health care workers

Disaster Medicine and Public Health Preparedness

Volumn 4, Issue 1, 2010, Pages 55-61

  Schneider, Ruth B ^a   Benitez, John G ^a,b   D'Angelo, Anne ^a   Tyo, Kathee ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY   (United States)

Author keywords

Antiviral drug; Hospital preparedness; Pandemic influenza; Stockpiling; Vaccination rates

Indexed keywords

ANTIVIRUS AGENT; INFLUENZA VACCINE;

ARTICLE; DISASTER PLANNING; DISEASE TRANSMISSION; E-MAIL; EPIDEMIC; HEALTH CARE PERSONNEL; HOSPITAL; HUMAN; IMMUNIZATION; IMMUNOLOGY; INFLUENZA; INFLUENZA VIRUS A H5N1; INFORMATION PROCESSING; ORGANIZATION AND MANAGEMENT; STATISTICS; UNITED STATES; VACCINATION;

ANTIVIRAL AGENTS; DATA COLLECTION; DISASTER PLANNING; DISEASE OUTBREAKS; DISEASE TRANSMISSION, INFECTIOUS; ELECTRONIC MAIL; HEALTH PERSONNEL; HOSPITALS; HUMANS; IMMUNIZATION; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; NEW YORK; VACCINATION;

EID: 77951640941     PISSN: 19357893     EISSN: 1938744X     Source Type: Journal    
DOI: 10.1097/DMP.0b013e3181cb4156     Document Type: Article

References (35)

1. Johnson N P A S, Mueller J. Updating the accounts: global mortality of the 1918-1920 "Spanish" influenza pandemic. Bull Hist Med. 2002;76:105-115.
2. Glezen WP. Emerging infections: pandemic influenza. Epidemiol Rev. 1996;18:64-76. (Pubitemid 26303555)
3. Taubenberger JK, Morens DM. 1918 influenza: the mother of all pandemics. Emerg Infect Dis. 2006. http://www.cdc.gov/NCIDOD/EID/vol12no01/05-0979.htm. Accessed December 28, 2009.
4. World Health Organization. Cumulative number of confirmed human cases of avian influenza A/(H5N1) reported to WHO 23 March 2009. http://www.who.int/csr/ disease/avian-influenza/country/cases-table-2009-03-23a/en/index.html. Accessed March 28, 2009.
5. Meltzer MI, Cox NJ, Fukuda K. The economic impact of pandemic influenza in the United States: priorities for intervention. Emerg Infect Dis. 1999;5:659-671. (Pubitemid 29493768)
6. Hayden FG. Perspectives on antiviral use during pandemic influenza. Phil Trans R Soc Lond. 2001;356:1877-1884. (Pubitemid 34099093)
7. American Academy of Pediatrics Committee on Infectious Diseases. Antiviral therapy and prophylaxis for influenza in children. Pediatrics. 2007;119:852-860.
8. Englund JA, Champlin RE, Wyde PR, et al. Common emergence of amantadine-and rimantadine-resistant influenza A viruses in symptomatic immunocompromised adults. Clin Infect Dis. 1998;26:1418-1424. (Pubitemid 28270175)
9. Moscona A. Neuraminidase inhibitors for influenza. N Engl J Med. 2005;353:1363-1373. (Pubitemid 41362704)
10. Monto AS, Webster A, Keene O. Randomized, placebo-controlled studies of inhaled zanamivir in the treatment of influenza A and B: pooled efficacy analysis. J Antimicrob Chemother. 1999;44:23-29. (Pubitemid 29531321)
11. Treanor JJ, Hayden FG, Vrooman PS, et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. JAMA. 2000;238:1016-1024. (Pubitemid 30112215)
12. Cooper NJ, Sutton AJ, Abrams KR, et al. Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: systematic review and meta-analyses of randomized trials. BMJ. 2003;326:1235.
13. Kaiser L, Wat C, Mills T, et al. Impact of oseltamivir treatment on influenzarelated lower respiratory tract complications and hospitalizations. Arch Intern Med. 2003;163:1667-1672. (Pubitemid 36898954)
14. Carr J, Ives J, Kelly L, et al. Influenza virus carrying neuraminidase with reduced sensitivity to oseltamivir carboxylate has altered properties in vitro and is compromised for infectivity and replicative ability in vitro. Antiviral Res. 2002;54:79-88. (Pubitemid 34327686)
15. Ives JA, Carr JA, Mendel DB, et al. The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo. Antiviral Res. 2002;55:307-317. (Pubitemid 34718130)
16. Centers for Disease Control and Prevention. CDC Issues Interim Recommendations for the Use of Influenza Antiviral Medications in the Setting of Oseltamivir Resistance Among Circulating Influenza A (H1N1) Viruses, 2008-09 Influenza Season. December 19, 2008. http://www2a.cdc.gov/HAN/ArchiveSys/ ViewMsgV.asp?AlertNum-00279. Accessed March 23, 2009.
17. Hayden FG. Antivirals for influenza: historical perspectives and lessons learned. Antiviral Res. 2006;71:372-378. (Pubitemid 44226490)
18. Simeonsson K, Summers-Bean C, Connolly A. Influenza vaccination of healthcare workers: institutional strategies for improving rates. N C Med J. 2004;65:323-329.
19. Leavitt MO. Pandemic Planning Update VI. January 8, 2009. http://www.flu.gov/professional/pdf/panflureport6.pdf. Accessed December 28, 2009.
20. Homeland Security Council. National Strategy for Pandemic Influenza: Implementation Plan One Year Summary July 2007. http://www.flu.gov/professional/ federal/pandemic-influenza-oneyear.pdf. Accessed December 17, 2009.
21. Gerdil C. The annual production cycle for influenza vaccine. Vaccine. 2003;21:1776-1779. (Pubitemid 36398372)
22. US Department of Health and Human Services, US Department of Homeland Security. Guidance on Allocating and Targeting Pandemic Influenza Vaccine. http://www.pandemicflu.gov/vaccine/allocationguidance.pdf. Accessed March 23, 2009.
23. US Department of Health and Human Services. Guidance on Antiviral Drug Use During an Influenza Pandemic. http://www.pandemicflu.gov/vaccine/antiviral- use.html. Accessed March 23, 2009.
24. US Department of Health and Human Services. Antivirals-State Allocations. http://www.pandemicflu.gov/plan/states/antivirals.html. Accessed March 23, 2009.
25. Homeland Security Council. Implementation plan for the national strategy for pandemic influenza. 2006; p 8. http://georgewbushwhitehouse.archives.gov/ homeland/pandemic-influenza-implementation.html. Accessed December 28, 2009.
26. Bullard WM. NYSDOH Teleconference. Pandemic Influenza Update. July 27, 2007.
27. Birkhead G. NYSDOH Statewide Videoconference. Allocation of Ventilators in an Influenza Pandemic. March 16, 2007.
28. American College of Physicians. The health care response to pandemic influenza. Ann Intern Med. 2006;145:135-137.
29. Center Comments. Comments from the Center for Biosecurity of UPMC on Draft Guidelines for Pandemic Influenza Planning. Biosecur Bioterrorism: Biodefense Strat Pract Sci. 2008;6:279-284.
30. US Department of Health and Human Services. Consideration for Antiviral Drug Stockpiling by Employers in Preparation for an Influenza Pandemic. http://www.pandemicflu.gov/vaccine/antiviral-employers.html. Accessed March 23, 2009.
31. Emmanuel EJ. The lessons of SARS. Ann Intern Med. 2003;139:589-591.
32. Qureshi K, Gerson RR, Sherman MF, et al. Health care workers' ability and willingness to report to duty during catastrophic disasters. J Urban Health. 2005;82:378-388. (Pubitemid 41191557)
33. Syrett JI, Benitez JG, Livingston WH 3rd, Davis EA. Will emergency health care providers respond to mass casualty incidents? Prehosp Emerg Care. 2007;11:49-54. (Pubitemid 46005642)
34. Gardam M, Liang D, Moghadas SM, et al. The impact of prophylaxis of healthcare workers on influenza pandemic burden. J R Soc Interface. 2007;4:727-734. (Pubitemid 47204171)
35. Cinti S, Cheoweth C, Monto AS. Preparing for pandemic influenza: should hospitals stockpile oseltamivir? Infect Control Hosp Epidemiol. 2005;26:852-854. (Pubitemid 41659341)